S9, Ep 15- COVID-19 Isn't Over for Everyone: Why FDA's Next Decision Matters for Immunocompromised Patients

The COVID-19 public health emergency may be over, but for millions of Americans with weakened immune systems, the virus remains a serious concern. In this episode of The Health Advocates, Steven Newmark breaks down a recent announcement from the U.S. Department of Health and Human Services to phase out COVID-19 Emergency Use Authorizations (EUAs) and explains why the decision matters for people who are immunocompromised. The transition will require the FDA to establish new regulatory pathways for certain COVID-19 drugs and biologics over the coming year, raising important questions about how patients will continue to access preventive therapies during that process. Steven explains what an EUA is, why some immunocompromised patients need additional protection beyond vaccination, and why patient voices are essential as the FDA considers its next steps. Most importantly, he discusses how thoughtful patient advocacy can help ensure that regulatory decisions remain focused on science, continuity of care, and the needs of those who remain most vulnerable to COVID-19. Whether you're living with a chronic illness, caring for someone who is immunocompromised, or simply interested in how health policy affects patient care, this episode offers an accessible look at an important issue that could shape COVID-19 prevention for years to come. Contact Our HostSteven Newmark, Chief of Policy at GHLF: [email protected] podcast episode produced by Amelia Violet Prouse, Associate Podcast & Video Producer at GHLF.We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to [email protected] to all episodes of The Health Advocates on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.